NeRRe Therapeutics
NeRRe Therapeutics is a UK-based clinical-stage biotech developing orvepitant, a neurokinin-1 receptor antagonist currently in Phase 2 trials for chronic cough associated with idiopathic pulmonary fibrosis, an indication with no approved targeted therapies.
- Company typePrivate
- Founded2012
- HeadquartersStevenage, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeRRe Therapeutics does
NeRRe Therapeutics is a privately-held clinical-stage biopharmaceutical company founded in 2012 and headquartered in Stevenage, United Kingdom. The company is developing orvepitant, a proprietary neurokinin-1 (NK1) receptor antagonist designed to block substance P signaling in vagal afferent nerves implicated in the cough reflex. Orvepitant is being advanced through Phase 2 clinical trials as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF), an indication with no currently approved targeted therapies. NeRRe Therapeutics operates as a single-asset, single-product biotech with no other compounds in its disclosed pipeline.
The company's business model is pre-revenue and dependent on venture capital financing to fund clinical development. NeRRe has raised approximately $74.6M across three funding rounds (2012, 2017, 2021), with the most recent being a £20M Series B2 in July 2021 led by Columbus Venture Partners, alongside Advent Life Sciences, Forbion, Fountain Healthcare Partners, OrbiMed, and The Future Fund. The company anticipates generating future revenue through direct commercialization or out-licensing of orvepitant to established pharmaceutical partners, with planned distribution through specialty pharmacy networks and hospital formularies targeting pulmonologists and respiratory specialists upon regulatory approval. The broader chronic refractory cough market spans an estimated 12.9 million cases in the US and significant patient populations across the EU4, UK, and Japan, providing substantial addressable market potential beyond the initial IPF indication.
NeRRe Therapeutics firmographics
Firmographics- Name
- NeRRe Therapeutics
- Website
- https://nerretherapeutics.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeRRe Therapeutics is a UK-based clinical-stage biotech developing orvepitant, a neurokinin-1 receptor antagonist currently in Phase 2 trials for chronic cough associated with idiopathic pulmonary fibrosis, an indication with no approved targeted therapies.
- Ownership category
- akta.pro rank
NeRRe Therapeutics industry classification
Industry- Product category
- Respiratory Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where NeRRe Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
NeRRe Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical product revenue: Pre-revenue clinical stage biopharmaceutical company. Expected to generate revenue through sales of orvepitant upon successful regulatory approval and commercialization for treatment of chronic cough associated with IPF and potentially other chronic cough indications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
NeRRe Therapeutics product offering
Product offeringCore offering
NeRRe Therapeutics is a clinical-stage biotechnology company developing orvepitant, a novel neurokinin-1 (NK1) receptor antagonist, as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). The drug candidate works by blocking substance P signaling in vagal afferent nerves involved in the cough reflex, and is currently advancing through Phase 2 clinical trials.
Product overview
NeRRe Therapeutics is a single-product biotech company focused on developing orvepitant, a novel neurokinin-1 receptor antagonist, as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). The company is advancing this drug candidate through Phase 2 clinical trials, funded by a £20 million Series B2 funding round. The company does not appear to offer a platform architecture or multiple products—their portfolio centers exclusively on this one therapeutic candidate.
Differentiator
Problem solved
Functional benefit
Products and services
- Orvepitant
Quantifiable outcome
- Phase 2 clinical trials in progress to establish efficacy for chronic cough treatment in IPF patients
Companies that use NeRRe Therapeutics
Customer profileSegments2 records
Ideal customer profiles1 record
NeRRe Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
NeRRe Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
NeRRe Therapeutics competitors and assessment
Company assessmentDirect peers
- Bellus Health: Canadian clinical-stage biotech developing P2X3 antagonists (camlipixant) for chronic cough. Direct competitor in the same patient population and indication NeRRe targets with a different mechanism of action.
- Neumentum: Clinical-stage company developing non-opioid therapeutics for chronic cough and pain, directly competing with NeRRe for the chronic refractory cough patient population.
- Cara Therapeutics: Biotech developing neurokinin-1 receptor antagonists (including oral and IV formulations) for pruritus and other indications. Directly comparable as an NK1-focused small-molecule developer.
- Pliant Therapeutics: Biotech developing therapeutics for idiopathic pulmonary fibrosis and other fibrotic diseases, directly overlapping with NeRRe's IPF patient population and chronic cough indication.
Broad incumbents
- Merck & Co. (via Afferent Pharma / gefapixant program): Merck advanced gefapixant, a P2X3 antagonist, through late-stage development and filings for refractory chronic cough. A large pharma incumbent directly competing for the same chronic cough patient population targeted by orvepitant.
- FibroGen: Developed pamrevlumab for IPF, directly relevant as a competitor targeting the same IPF patient population that NeRRe addresses for the chronic cough symptom.
- United Therapeutics: Commercial-stage company marketing Tyvaso (treprostinil) for pulmonary hypertension and PH-ILD, including IPF patients. A relevant incumbent in IPF therapeutics with overlapping patient reach.
- Boehringer Ingelheim (Ofev / nintedanib): Markets nintedanib (Ofev), one of two FDA-approved therapies for IPF. The dominant standard-of-care incumbent whose IPF patient population overlaps NeRRe's targeted cough indication.
Emerging players
- Trevena: Clinical-stage biopharmaceutical company focused on CNS and respiratory indications with novel small-molecule therapies, broadly comparable in stage and therapeutic area focus to NeRRe.
- Galapagos NV: Biotech that advanced ziritaxestat and other IPF candidates through clinical development, providing a comparable clinical-stage IPF competitor with similar development-stage profile to NeRRe.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NeRRe Therapeutics social profiles
Digital presenceNeRRe Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeRRe Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
NeRRe Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeRRe Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeRRe Therapeutics
What does NeRRe Therapeutics do?
NeRRe Therapeutics is a clinical-stage biotechnology company developing orvepitant, a novel neurokinin-1 (NK1) receptor antagonist, as a targeted treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF). The drug candidate works by blocking substance P signaling in vagal afferent nerves involved in the cough reflex, and is currently advancing through Phase 2 clinical trials.
Is NeRRe Therapeutics a public or private company?
NeRRe Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeRRe Therapeutics founded?
NeRRe Therapeutics was founded in 2012. It employs 11 to 50 people.
Where is NeRRe Therapeutics based?
NeRRe Therapeutics is headquartered in Stevenage, United Kingdom, in the Europe region.
How does NeRRe Therapeutics make money?
One revenue line is on record: pharmaceutical product revenue.
Who are NeRRe Therapeutics's main competitors?
Direct peers on record are Bellus Health, Neumentum, Cara Therapeutics and Pliant Therapeutics. Broad incumbents are Merck & Co. (via Afferent Pharma / gefapixant program), FibroGen, United Therapeutics and Boehringer Ingelheim (Ofev / nintedanib). Emerging players are Trevena and Galapagos NV.
Does NeRRe Therapeutics have an API?
No public API is recorded for NeRRe Therapeutics.
What industry is NeRRe Therapeutics in?
NeRRe Therapeutics's product category is Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.